MRKR · XBRL financial data

Marker Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MRKR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	500	0	—	—	—	—
Research and development	18,881	27,795	26,139	10,417	13,468	11,799
General and administrative	10,472	12,925	12,820	7,476	4,242	4,185
Total operating expenses	29,353	40,720	38,959	17,893	17,709	16,437
Operating income (loss)	(28,886)	(39,478)	(29,946)	(14,581)	(11,118)	(12,890)
Interest income	149	6	248	539	437	594
Income tax expense (benefit)	—	—	—	4	50	(15)
Net income (loss)	(28,706)	(41,879)	(29,931)	(8,237)	(10,731)	(12,164)
Earnings per share, basic USD per share	(0.61)	(0.55)	(3.58)	(0.94)	(1.19)	(0.79)
Earnings per share, diluted USD per share	(0.61)	(0.55)	(3.58)	(0.94)	(1.19)	(0.79)
Weighted average shares, basic thousands of shares	47,040	76,506	8,351	8,809	8,980	15,310
Weighted average shares, diluted thousands of shares	47,040	76,506	8,351	8,809	8,980	15,310

Fiscal years (MRKR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	21,352	42,351	11,782	15,111	19,192	16,068
Prepaid and other current assets	—	—	—	—	484	659
Total current assets	24,411	45,982	16,619	17,127	22,023	19,071
Property and equipment, net	10,360	12,323	12,323	—	—	—
Right-of-use asset	10,844	9,830	5,480	—	—	—
Total assets	45,615	68,135	34,422	17,127	22,023	19,071
Accounts payable	2,935	5,144	1,612	961	1,066	794
Total current liabilities	6,402	12,902	7,782	3,075	3,464	2,274
Lease liability, non-current	11,868	11,248	7,039	—	—	—
Total liabilities	18,270	24,150	14,821	3,075	3,464	2,274
Accumulated deficit	(356,239)	(398,118)	(428,049)	(436,286)	(447,017)	(459,181)
Total stockholders' equity	27,345	43,986	19,601	14,053	18,558	16,797
Total liabilities and equity	45,615	68,135	34,422	17,127	22,023	19,071
Common shares outstanding (cover page) thousands of shares	50,731	83,079	8,799	8,903	10,709	16,673

Fiscal years (MRKR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(28,706)	(41,879)	(29,931)	(8,237)	(10,731)	(12,164)
Stock-based compensation	5,228	5,964	5,344	858	246	538
Depreciation and amortization	486	2,149	2,789	—	—	—
Net cash from operating activities	(18,860)	(27,280)	(26,972)	(16,440)	(10,910)	(12,014)
Net cash from investing activities	(10,428)	(3,131)	(4,945)	18,664	—	—
Proceeds from issuing common stock	6,186	52,553	202	1,015	14,929	9,864
Net cash from financing activities	6,736	52,556	202	1,105	14,991	9,864
Net change in cash	—	43,500	11,800	—	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Cognition Therapeutics	34,012	not reported	(3,053)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.